Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of September 30, 2013:
- Total Issued Ordinary Shares: 5,365,498,851 (25p each)
- Treasury Shares: 479,674,412
- Total Voting Rights: 4,885,824,439
No comparative data for prior periods is included in this specific filing to determine material changes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,885,824,439) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (479,674,412) when calculating diluted metrics.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance data.